Komori
Results4892Cyfuse Biomedical K.K.Pharmaceuticals

Summary of Financial Results for the Third Quarter of the Fiscal Year Ending December 2026 [Japanese GAAP] (Non-consolidated)

Cumulative sales for the first 3 quarters increased 84.7% year on year, and the operating loss narrowed. Meanwhile, the ordinary loss and quarterly net loss widened, mainly due to a decrease in grant income.

Worth reading
37Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
84.7
Year-on-year change in net sales (%)
Wording
Conditional
How definitive the wording is.

Results for this period

Third quarter1 January 2026–30 September 2026Non-consolidated (standalone)Japanese GAAP
Net Sales114¥ millionYear on year +84.7%Progress 41.0%
Operating profit-628¥ million
Ordinary income-648¥ million
Net income attributable to owners of the parent-650¥ million

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.

Net income per share-¥64.83
Financial position at period-end
Total assets3,601¥ million
of which net assets 2,419 ¥ millionEquity ratio 63.4%vs. prior year-end +1.1pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥278 million (YoY +20.4%)
Operating profit¥-1,081 million
Ordinary income¥-1,056 million
Net income¥-1,059 million
Annual Dividend Forecast¥0.00 → ¥0.00(0.0%)
Factors Behind Changes in Business Performance

Sales increased due to various contract services related to 3D cell products and sales of related consumables. The operating loss narrowed as selling, general and administrative expenses decreased, but the ordinary loss and quarterly net loss widened due to a decrease in non-operating income and an increase in non-operating expenses.

Disclosure regarding the going concern assumption

No matters to report

Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Material subsequent eventsNo matters to report
Depreciation and amortization¥18,458 thousand
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNo
Issued Shares at Period-End10,092,100 shares
Treasury Shares at Period-End— shares
Results for this period
ItemDetails
Fiscal Period ClassificationThird quarter
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedNon-consolidated (standalone)
Period Covered1 January 2026–30 September 2026
Net Sales¥114 million (YoY +84.7%)
Operating profit¥-628 million
Ordinary income¥-648 million
Profit attributable to owners of the parent¥-650 million
Net income per share-¥64.83
Equity ratioEnd of the current fiscal period 63.4% / End of previous period 62.3%
Total assets¥3,601 million
Net assets¥2,419 million
Full-year earnings forecastNet Sales ¥278 million (YoY +20.4%) / Operating profit ¥-1,081 million / Ordinary income ¥-1,056 million / Net income ¥-1,059 million
Annual Dividend Forecast¥0.00 → ¥0.00(0.0%)
Depreciation and amortization¥18,458 thousand
Disclosure regarding the going concern assumptionNo matters to report
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No
Material subsequent eventsNo matters to report
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNo
Issued Shares at Period-End10,092,100 shares
Treasury Shares at Period-End— shares
Factors Behind Changes in Business PerformanceSales increased due to various contract services related to 3D cell products and sales of related consumables. The operating loss narrowed as selling, general and administrative expenses decreased, but the ordinary loss and quarterly net loss widened due to a decrease in non-operating income and an increase in non-operating expenses.
Items this document does not state (15)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogImpairment lossBreakdown of extraordinary income (loss)Changes in the scope of consolidation

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Sales increased due to various contract services related to 3D cell products and sales of related consumables, while the operating loss narrowed as selling, general and administrative expenses decreased. Meanwhile, the ordinary loss and quarterly net loss widened due to a decrease in non-operating income, including grants received for research and development, and an increase in non-operating expenses.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Summary of Financial Results for the Third Quarter of the Fiscal Year Ending December 2026 [Japanese GAAP] (Non-consolidated) | Cyfuse Biomedical K.K. (4892) timely disclosure | Komori